Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Proteome, Moffitt in clinical mass spectrometry assay collaboration

Proteome Sciences has agreed to support Moffitt Cancer Center in developing mass spectrometry assays measuring certain key signaling and repair pathway proteins that can be adapted for tumour biopsy analysis.

Proteome Sciences delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Moffitt Cancer Center is a member of the National Comprehensive Cancer Network.

Principal Investigator at Moffitt John Koomen said with this technical collaboration and support from Proteome Sciences they can extend the group’s activities to incorporate a large number of key proteins and post-translational modifications to rapidly translate laboratory tests into the direct management of cancer patients.

"We believe that knowledge of the molecular switches operating within each individual tumour will allow better selection and monitoring of treatment efficacy," Koomen said.

Proteome Sciences COO Ian Pike said there has been tremendous progress in the ability of mass spectrometers to selectively measure subtle changes in the proteins involved in cellular signaling and repair.

"New methods capable of simultaneously measuring these changes across several pathways are urgently needed to deliver better outcomes in all cancers," Pike said.

"We identified the expertise of the Koomen lab as being highly complementary to our own focus of profiling post-translational modifications in major human disease. We are delighted to be working with John and look forward to launching a number of new MS assays arising from this collaboration."